New drug duo targets Hard-to-Treat cancers in phase 2 trial
NCT ID NCT07318649
First seen Jan 09, 2026 · Last updated May 15, 2026 · Updated 17 times
Summary
This study tests a combination of two experimental drugs (GH21 and D-1553) in 120 adults with advanced solid tumors that have a specific genetic change called KRASG12C. Participants must have already tried standard treatments or have no standard options, and have previously taken a KRASG12C inhibitor. The goal is to see if the combination shrinks tumors and is safe, with treatment continuing as long as it helps and side effects are manageable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LOCALLY ADVANCED OR METASTATIC SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.